Literature DB >> 29927667

Using sertraline in postpartum and breastfeeding: balancing risks and benefits.

Alessandro Cuomo1, Giuseppe Maina2, Stephen M Neal3, Graziella De Montis1, Gianluca Rosso2, Simona Scheggi1, Bruno Beccarini Crescenzi1, Simone Bolognesi1, Arianna Goracci1, Anna Coluccia4, Fabio Ferretti4, Andrea Fagiolini1.   

Abstract

INTRODUCTION: The World Health Organization recommends newborns to be breastfed but this may be challenging if the mother needs to be treated for depression, since strong evidence to inform treatment choice is missing. AREAS COVERED: We provide a critical review of the literature to guide clinicians who are considering sertraline for the management of depression during postpartum. EXPERT OPINION: Sertraline is one of the safest antidepressants during breastfeeding. In most cases, women already taking sertraline should be advised to breastfeed and continue the medication. We recommend to begin with low doses and to slowly increase the dose up, with careful monitoring of the newborn for adverse effects (irritability, poor feeding, or uneasy sleep, especially if the child was born premature or had low weight at birth). The target dose should be the lowest effective. When feasible, child exposure to the medication may be reduced by avoiding breastfeeding at the time when the antidepressant milk concentration is at its peak. A decision to switch to sertraline from ongoing and effective treatment should be taken only after a scrupulous evaluation of the potential risks and benefits of switching versus continuing the ongoing medication while monitoring the infant carefully.

Entities:  

Keywords:  SSRI; Sertraline; breast-feeding; depression; infant; lactation; milk; newborn; nursing; perinatal and pregnancy; post-partum; pregnancy

Mesh:

Substances:

Year:  2018        PMID: 29927667     DOI: 10.1080/14740338.2018.1491546

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  1 in total

1.  Editorial: Reproductive Events in Women With Mood Disorders: Advances in Knowledge and Management.

Authors:  Gianluca Rosso; Prabha S Chandra
Journal:  Front Psychiatry       Date:  2021-11-30       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.